Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Lexaria Bioscience Corp. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 14 | 15 | +1 |
| Shares | 892.7K | 1.77M | +878.8K (+98.4%) |
| Value | $651.4K | $1.77M | +$1.12M (+171.8%) |
New holders (3)
Institutions that held Lexaria Bioscience Corp. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 889,272 | $889.2K | 0.03% |
| Two Sigma Securities, LLC | 10,545 | $10.5K | 0.00% |
| Gables Capital Management Inc. | 13 | $13 | 0.00% |
Sold out (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 15,426 | $11.2K |
| UBS Group AG | 99 | $72 |